BiotechTube
Molecure

Molecure

MOC.WA
Warsaw, Poland· Est.
molecure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $27.7M

Overview

Molecure is a clinical-stage biotech with a mission to develop novel small molecule drugs for high-unmet-need diseases in oncology and inflammation. Its key achievement is building two proprietary discovery platforms targeting RNA and protein-protein interactions (PPIs), translating into a maturing internal pipeline. The company's strategy involves advancing its lead programs through clinical proof-of-concept while leveraging its platforms for new discovery and potential partnerships. Its 2021 IPO on the Warsaw Stock Exchange provided capital to execute this strategy and establish Poland as a hub for innovative drug discovery.

OncologyInflammatory Diseases

Technology Platform

Proprietary platforms for discovering small molecules that target structured RNA elements and modulate protein-protein interactions (PPIs), focusing on historically undruggable targets.

Funding History

3
Total raised:$27.7M
IPO$15.2M
Series A$10M
Grant$2.5M

Opportunities

Validating its first-in-class clinical assets (OATD-01, OATD-02) could unlock significant partnership value and establish its platforms as engines for novel drug discovery.
The growing interest in RNA-targeting and PPI-modulating small molecules creates a favorable environment for platform validation and deal-making.
Its position as a Central European biotech leader offers access to scientific talent and grant funding with cost-efficient operations.

Risk Factors

High clinical risk associated with novel mechanisms of action; lead program failure would impact platform credibility.
Future financing needs are substantial and subject to volatile equity markets.
Intense competition in fibrosis and immuno-oncology requires clear differentiation.
Global commercialization will necessitate partnerships, introducing dependency on third parties.

Competitive Landscape

Competes in fibrosis with established anti-fibrotics and novel agents, and in immuno-oncology with other arginase pathway inhibitors. Its RNA platform faces competition from well-funded US biotechs like Arrakis and Skyhawk. Differentiation hinges on demonstrating clinical efficacy with its unique compounds and leveraging its integrated, cost-efficient R&D model.

More companies in Small Molecule Drugs →More companies in Poland →